CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Core Viewpoint - Corcept Therapeutics Inc. is under investigation by Block & Leviton for potential securities law violations following a significant drop in its stock price after receiving a Complete Response Letter from the FDA regarding its drug relacorilant [1][2]. Group 1: Company Overview - Corcept Therapeutics' shares fell more than 50% on December 31, 2025, due to the FDA's Complete Response Letter indicating the need for additional evidence of effectiveness for relacorilant [2]. - The company is facing scrutiny as investors who have lost money in their investments are encouraged to contact Block & Leviton for potential recovery options [1][3]. Group 2: Legal Investigation - Block & Leviton is investigating whether Corcept Therapeutics committed securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased Corcept Therapeutics common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. Group 3: Whistleblower Information - Individuals with non-public information about Corcept Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].